CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis
(WorldNews Switzerland)

Basel, 21 September 2018 CHMP recommends EU approval for subcutaneous formulation of RoActemra for use in active systemic juvenile idiopathic arthritis (sJIA), a rare form of juvenile arthritis Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the subcutaneous (SC) formulation of RoActemra® (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients one year of age and older. RoActemra can be given alone or in combination with methotrexate (MTX) in patients with sJIA. In 2011, the European Commission approved the intravenous (IV) formulation of...